ADMA Biologics Liabilities 2024

ADMA Biologics Aktienanalyse

What does ADMA Biologics do?

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing ADMA Biologics's Liabilities

ADMA Biologics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ADMA Biologics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ADMA Biologics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ADMA Biologics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ADMA Biologics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ADMA Biologics stock

What is the level of liabilities of ADMA Biologics this year?

ADMA Biologics has a debt balance of 193.98 M USD this year.

What were the liabilities of ADMA Biologics compared to the previous year?

The liabilities of ADMA Biologics have increased by -1.28% dropped compared to the previous year.

What are the consequences of high debt for investors of ADMA Biologics?

High liabilities can pose a risk for investors of ADMA Biologics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in ADMA Biologics?

Low liabilities mean that ADMA Biologics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of ADMA Biologics affect the company?

An increase in liabilities of ADMA Biologics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of ADMA Biologics affect the company?

A decrease in the liabilities of ADMA Biologics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of ADMA Biologics?

Some factors that can influence the liabilities of ADMA Biologics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of ADMA Biologics so important for investors?

The liabilities of ADMA Biologics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can ADMA Biologics take to modify the liabilities?

To change its liabilities, ADMA Biologics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does ADMA Biologics pay?

Over the past 12 months, ADMA Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADMA Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADMA Biologics?

The current dividend yield of ADMA Biologics is .

When does ADMA Biologics pay dividends?

ADMA Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADMA Biologics?

ADMA Biologics paid dividends every year for the past 0 years.

What is the dividend of ADMA Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADMA Biologics located?

ADMA Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADMA Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADMA Biologics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did ADMA Biologics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of ADMA Biologics in the year 2023?

In the year 2023, ADMA Biologics distributed 0 USD as dividends.

In which currency does ADMA Biologics pay out the dividend?

The dividends of ADMA Biologics are distributed in USD.